Overview

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This research study is testing if Talazoparib is an effective treatment for patients with AML and MDS that have a mutation in the cohesin complex.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Pfizer
Treatments:
Talazoparib